Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Abbott Laboratories, consolidated balance sheet: assets

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash and cash equivalents	6,896)	9,882)	9,799)	6,838)	3,860)
Investments, primarily bank time deposits and U.S. treasury bills	383)	288)	450)	310)	280)
Trade receivables, less allowances	6,565)	6,218)	6,487)	6,414)	5,425)
Inventories	6,570)	6,173)	5,157)	5,012)	4,316)
Other prepaid expenses and receivables	2,256)	2,663)	2,346)	1,867)	1,786)
Current assets	22,670)	25,224)	24,239)	20,441)	15,667)
Equity securities	555)	558)	748)	776)	836)
Other	244)	208)	68)	45)	47)
Long-term investments	799)	766)	816)	821)	883)
Net property and equipment	10,154)	9,162)	8,959)	9,029)	8,038)
Intangible assets, net of amortization	8,815)	10,454)	12,739)	14,784)	17,025)
Goodwill	23,679)	22,799)	23,231)	23,744)	23,195)
Deferred income taxes and other assets	7,097)	6,033)	5,212)	3,729)	3,079)
Long-term assets	50,544)	49,214)	50,957)	52,107)	52,220)
Total assets	73,214)	74,438)	75,196)	72,548)	67,887)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Abbott Laboratories current assets increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Net property and equipment	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	Abbott Laboratories net property and equipment increased from 2021 to 2022 and from 2022 to 2023.
Long-term assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	Abbott Laboratories long-term assets decreased from 2021 to 2022 but then increased from 2022 to 2023 not reaching 2021 level.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	Abbott Laboratories total assets decreased from 2021 to 2022 and from 2022 to 2023.

Current Assets: Selected Items

Download chart

Balance sheet item	Description	The company
Cash and cash equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	Abbott Laboratories cash and cash equivalents increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.
Investments, primarily bank time deposits and U.S. treasury bills	Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.	Abbott Laboratories investments, primarily bank time deposits and U.S. treasury bills decreased from 2021 to 2022 but then increased from 2022 to 2023 not reaching 2021 level.
Trade receivables, less allowances	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	Abbott Laboratories trade receivables, less allowances decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Inventories	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	Abbott Laboratories inventories increased from 2021 to 2022 and from 2022 to 2023.

Abbott Laboratories (NYSE:ABT)

Balance Sheet: Assets

Assets: Selected Items

Current Assets: Selected Items